A Sputnik moment: China's beating the US in neuroscience

2026-06-11 · Source: Semafor · Field: Health & Wellbeing — Medical Devices & Health Technology, Healthcare Systems & Policy, Life Sciences & Biology · Depth: Fundamental Awareness, extended

Summary

The United States risks losing its leadership in healthcare and science to China due to slow medical research and regulatory systems, according to Max Hodak, former Neuralink president and current head of Science Corp. Hodak warned that within 10 years, wealthy Americans might need to travel to Shanghai for advanced cancer care. This concern is underscored by China's recent approval of the first commercially available brain-computer interface (BCI), surpassing the US, and its designation of BCIs as a key national priority. Hodak's firm, Science Corp., is developing retinal implants to restore vision for macular degeneration patients, having raised \$230 million in March, and also works on organ preservation technology for transplants. The rapid progress in China highlights the urgent need for US regulatory reform to maintain its competitive edge in neurotechnology and advanced medical treatments.

Key takeaway

For US policymakers and healthcare executives weighing future investment and regulatory strategies, China's swift progress in neurotechnology and BCI commercialization demands immediate attention. Your current regulatory frameworks risk ceding leadership in critical medical and scientific fields, potentially forcing advanced care seekers abroad within a decade. You should prioritize comprehensive regulatory reform and strategic national investment in neurotechnology to secure domestic innovation and patient access.

Key insights

China's rapid neurotechnology advancements, driven by national priority and faster regulation, challenge US scientific preeminence.

Principles

• Regulatory speed impacts innovation leadership.
• National priorities accelerate tech development.
• Early commercialization secures market advantage.

In practice

• Invest in BCI and neurotechnology research.
• Streamline medical device approval processes.
• Prioritize strategic scientific fields nationally.

Topics

• Neurotechnology
• Brain-Computer Interfaces
• Medical Regulatory Reform
• US-China Tech Competition
• Healthcare Preeminence
• Retinal Implants

Best for: Investor, CTO, Entrepreneur, Policy Maker, Executive, Director of AI/ML

Related on AIssential

• China has approved the world’s first invasive brain-computer chip—here’s what’s next — China's NEO BCI, less invasive and government-backed, is the first globally approved for commercial use, offering hope for paralysis patients.
• FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder — Navigating highly regulated sectors like healthcare demands rigor, early regulatory engagement, and a resilient company culture.
• Nvidia CEO to join board of elite Chinese university — Rapid AI advancement is creating complex geopolitical, ethical, and infrastructural challenges, necessitating urgent global governance.
• What It’s Like to Live With an Experimental Brain Implant — Brain-computer interfaces are moving from labs to medical use, offering profound benefits despite significant user commitment and technical challenges.
• ‘The next big thing’: Newfund raises €60m to back brain technologies — Brain technologies represent a significant growth opportunity, driven by scientific maturity and advanced tools like AI.
• The Download: China’s brain implant ambitions — Rapid technological advancements in AI and biotech are met with increasing geopolitical tensions and environmental concerns.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Semafor.